Meeting
2014 ASCO Annual Meeting
Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial.
Authors
Jose Maria Piulats Rodriguez
Institut Català d'Oncologia de l'Hospitalet, Barcelona, Spain
Jose Maria Piulats Rodriguez , Maria Ochoa de Olza , Manuel Codes , Jose A. Lopez-Martin , Alfonso Berrocal , Margarita García , Alfonso Gurpide , Blanca Homet , Salvador Martin-Algarra
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
2010-024415-14
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 9033)
DOI
10.1200/jco.2014.32.15_suppl.9033
Abstract #
9033
Poster Bd #
49
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962.
First Author: Josep M. Piulats
Poster
2013 ASCO Annual Meeting
BEVATEM: Phase II study of bevacizumab (B) in combination with temozolomide (T) in patients (pts) with first-line metastatic uveal melanoma (MUM): Final results.
First Author: Sophie Piperno-Neumann
Poster
2022 ASCO Annual Meeting
Safety and efficacy of combined melphalan percutaneous hepatic perfusion (M-PHP) and ipilimumab plus nivolumab (IPI+NIVO) in metastasized uveal melanoma (mUM): First results of the phase Ib part of the CHOPIN trial.
First Author: Thaïs M.L. Tong
Poster
2021 ASCO Annual Meeting
Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma.
First Author: Marlana Orloff